Cutaneous melanoma: pathogenesis and rationale for chemoprevention

被引:14
作者
Demierre, MF
Sondak, VK
机构
[1] Boston Univ, Sch Med, Boston Med Ctr, Dept Dermatol,Skin Oncol Program, Boston, MA 02118 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary oncol, Cutaneous Oncol Program, Tampa, FL USA
关键词
melanoma; pathogenesis; chemoprevention;
D O I
10.1016/j.critrevonc.2004.11.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To critically review aspects of melanoma pathogenesis that lend themselves to a chemoprevention strategy. To discuss potential candidate chemoprevention agents with an emphasis on the lipid lowering drugs, the statins, currently, the most promising agents. Data sources: A retrospective review of the literature. Study, selection: Studies included those relevant to melanoma pathogenesis, to the scientific rationale of chemoprevention, and pertinent epidemiologic, pre-clinical, and clinical studies. The referenced study designs and methodologies varied. Data extraction and synthesis: Data were extracted by two reviewers, and the main results are presented in a quantitative descriptive manner. Conclusion: Melanoma is a preventable disease by altering behavior (sun exposure) among at-risk individuals. There is also considerable evidence to suggest that melanoma development may be prevented or delayed by drugs of sufficiently low toxicity to make clinical trials of chemoprevention feasible and potentially successful. Among potential candidate agents, statins have compelling data for long-term safety and sufficient pre-clinical and clinical evidence for efficacy to justify their evaluation in well-designed trials in high-risk individuals, incorporating intermediate biologic endpoints. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:225 / 239
页数:15
相关论文
共 235 条
[31]   Lack of BRAF mutation in primary uveal melanoma [J].
Cohen, Y ;
Goldenberg-Cohen, N ;
Parrella, P ;
Chowers, I ;
Merbs, SL ;
Pe'er, J ;
Sidransky, D .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (07) :2876-2878
[32]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[33]  
Collisson EA, 2003, MOL CANCER THER, V2, P941
[34]   Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells [J].
Collisson, EA ;
Carranza, DC ;
Chen, IY ;
Kolodney, MS .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (05) :1172-1176
[35]  
COLLISSON EA, 2003, P INT INV DERM M
[36]   DYSPLASTIC NEVI - OCCURRENCE IN 1ST-DEGREE AND 2ND-DEGREE RELATIVES OF PATIENTS WITH SPORADIC DYSPLASTIC NEVUS SYNDROME [J].
CRIJNS, MB ;
VINK, J ;
VANHEES, CLM ;
BERGMAN, W ;
VERMEER, BJ .
ARCHIVES OF DERMATOLOGY, 1991, 127 (09) :1346-1351
[37]  
CRUTCHER WA, 1984, LANCET, V1, P729
[38]  
Cruz F, 2003, CANCER RES, V63, P5761
[39]   SPECIFIC LABELING OF ISOPRENYLATED PROTEINS - APPLICATION TO STUDY INHIBITORS OF THE POSTTRANSLATIONAL FARNESYLATION AND GERANYLGERANYLATION [J].
DANESI, R ;
MCLELLAN, CA ;
MYERS, CE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 206 (02) :637-643
[40]   Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer [J].
Dannenberg, AJ ;
Altorki, NK ;
Boyle, JO ;
Dang, C ;
Howe, LR ;
Weksler, BB ;
Subbararnaiah, K .
LANCET ONCOLOGY, 2001, 2 (09) :544-551